Abstract
Background
Hepatitis C virus (HCV) is one of the major causes of liver cancer. The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-λ3, are strongly associated with the response to pegylated IFN-α (PEG-IFN-α) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. However, the roles of IFN-λ3 in chronic HCV infection are still elusive. In this study, we aimed to identify clinical and immunological factors influencing IFN-λ3 and evaluated whether serum IFN-λ3 levels are involved or not involved in the response to PEG-IFN-α plus RBV therapy.
Methods
We enrolled 119 C-CH patients with HCV genotype 1 infection who underwent 48 weeks of PEG-IFN-α plus RBV therapy. As controls, 23 healthy subjects and 56 patients with non-HCV viral hepatitis were examined. Serum IFN-λ3 was quantified by chemiluminescence enzyme immunoassay, and 27 cytokines or chemokines were assayed by the multiplexed BioPlex system.
Results
Serum IFN-λ3 levels were higher in C-CH patients or acute hepatitis E patients than in healthy volunteers. Such levels did not differ between the IFNL3 genotypes. In C-CH patients, serum IFN-λ3 was positively correlated with aspartate aminotransferase, alanine aminotransferase, α-fetoprotein, histological activity, fibrosis index, IFN-γ-inducible protein 10, and platelet-derived growth factor. Multivariate analysis showed that IFNL3 single nucleotide polymorphisms, fibrosis score, and macrophage inflammatory protein 1α were involved in the sustained viral clearance in PEG-IFN-α plus RBV therapy; however, serum IFN-λ3 levels were not involved.
Conclusion
Serum IFN-λ3 levels are increased in C-CH patients regardless of the IFNL3 genotype. IFN-λ3 is a biomarker reflecting the activity and fibrosis of liver disease, but is not correlated with the responsiveness to PEG-IFN-α plus RBV therapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hepatitis C virus (HCV) is one of the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC), with nearly 170 million people infected worldwide [1]. A combination therapy with pegylated interferon (IFN)-α (PEG-IFN-α) and ribavirin (RBV) has been used for chronic hepatitis C (C-CH) patients as the standard of care, achieving sustained virological response (SVR) in 42–52 % of genotype 1 patients [2]. Even in the coming era of all oral and IFN-free regimens for the treatment of C-CH patients [3–5], PEG-IFN-α plus RBV therapy could hold promise for elderly patients with advanced fibrosis and high risk of HCC.
Genome-wide association studies, including ours, have demonstrated that single nucleotide polymorphisms (SNPs) upstream of the promoter region within the IFNL3 gene (also known as IL28B), which encodes a type III IFN (IFN-λ3), are strongly associated with the response to PEG-IFN-α plus RBV therapy in C-CH patients [6–9]. Although such significant impact of the IFNL3 genotype on the outcome of the combination therapy is well acknowledged, the biological and clinical roles of IFN-λ3 in chronic HCV infection are still elusive. Furthermore, it is controversial if patients with the IFNL3 major genotype are capable of producing larger amounts of IFN-λ3 than those with the minor genotype.
The IFN-λ family consists of several subtypes, such as IFN-λ1 (IL-29), IFN-λ2 (IL-28A), and IFN-λ3 (IL-28B), which are biologically active for the suppression of HCV replication [10, 11]. On initial exposure to HCV, primary human hepatocytes in vitro produced IFN-λ and subsequently induced antiviral IFN-stimulated genes [12]. It is thus rational to consider that the more IFN-λ family members are produced in the exposed hosts, the more likely they are to protect the hosts from HCV virulence in the primary infection. However, in chronically HCV-infected patients, it has not been proven that such a scenario could be applicable for the outcome of the disease.
To gain insight into the role of IFN-λ3 in chronic HCV infection, we aimed to clarify the factors influencing serum IFN-λ3 levels, including IFNL3 genotype, clinical parameters, and various cytokines and chemokines. For application in clinical practice, we evaluated whether serum IFN-λ3 levels are associated or not associated with the response to PEG-IFN-α plus RBV therapy for C-CH patients.
Materials and methods
Study subjects
One hundred nineteen Japanese patients with C-CH (genotype 1b and high viral load) were enrolled in the study. All patients were negative for hepatitis B virus (HBV) and human immunodeficiency virus (HIV) and did not have any other chronic liver diseases, such as alcoholic, autoimmune, and fatty liver disease. The presence of HCC was ruled out by ultrasonography or computed tomography examinations. The patients had been followed at the National Center for Global Health and Medicine Kohnodai Hospital, the National Hospital Organization Nagasaki Medical Center, Shin-Kokura Hospital, and Musashino Red Cross Hospital. They were treated with PEG-IFN-α2b (subcutaneously once a week; 1.5 μg/kg body weight) or PEG-IFN-α2a (180 μg once a week) plus RBV (600–1,000 mg daily depending on body weight) for 48 weeks according to the guidelines of the Japan Society of Hepatology [13]. Virological response to the combination therapy was defined according to the practical guidelines of the American Association for the Study of Liver Diseases [14]. All patients attained adherence to PEG-IFN-α plus RBV therapy exceeding 80 % of the estimated total dose. Liver biopsy was performed before the start of the therapy. Histological activity and fibrosis were determined according to the METAVIR scoring system [15]. Serum samples were collected from the patients before PEG-IFN-α plus RBV treatment started and were stored at −80 °C. In some patients, the samples were obtained 24 weeks after the cessation of the therapy (at the end of follow-up).
As controls, serum was obtained from 23 healthy subjects without HCV, HBV, and HIV infection (male-to-female ratio, 5:5, mean age ± standard deviation, 45 ± 12 years). In the comparison of serum IFN-λ levels between C-CH patients and patients with other types of liver diseases, 11 patients with chronic HBV infection (three HBeAg-positive patients and eight HBeAg-negative patients) were examined as well. They were not treated with IFN or nucleot(s)ide analogues for HBV infection. In addition, we compared serum IFN-λ3 levels among patients with acute viral hepatitis of various causes, such as acute hepatitis A, acute hepatitis B, or acute hepatitis E, the diagnosis of which was determined by serological examinations at Teine Keijinkai Hospital and Kurume University Hospital. The serum samples were obtained from the patients at the time of active liver inflammation [alanine aminotransferase (ALT) levels more than two times the upper limit of the normal range]. As representatives for noninvasive fibrosis markers, the fibrosis-4 (FIB-4) score and the aspartate aminotransferase (AST) platelet ratio index (APRI) were calculated as reported previously [16, 17].
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board at the National Center for Global Health and Medicine (approval ID and date, NCGM-G-001379-00, March 14, 2013) and the ethical committee of each institute. Written informed consent was obtained from all patients.
IFNL3 genotyping
The subjects were evaluated for SNPs near the IFNL3 gene (rs8099917) using the Invader Plus assay (Invader Chemistry, Madison, WI, USA) as previously reported [18]. The TT, TG, and GG genotypes were determined accordingly.
Measurement of serum IFN-λ3
Serum levels of IFN-λ3 were evaluated by the newly developed chemiluminescence enzyme immunoassay system as reported previously [19]. The system enables one to quantify serum IFN-λ3 specifically without any overlap from IFN-λ1 and IFN-λ2. The threshold of the assay is 10 pg/mL and its range is 10–1,000 pg/mL.
Simultaneous measurement of multiple chemokines and cytokines
To quantify multiple chemokines and cytokines simultaneously in the limited volume of the samples, we used the BioPlex 3D system (BioPlex Pro Human GI 27Plex; Bio-Rad, Hercules, CA, USA) for the study. In this system, 27 chemokines and cytokines were measurable, such as basic fibroblast growth factor, eotaxin, granulocyte colony stimulating factor, granulocyte–macrophage colony stimulating factor, IL-1β, IL-1 receptor antagonist, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-γ, IFN-γ-inducible protein 10 (IP-10), monocyte chemotactic protein 1, macrophage inflammatory protein (MIP)-1α, MIP-1β, platelet-derived growth factor BB (PDGF-BB), regulated on activation, normally T cell expressed, and secreted (RANTES), TNF-α, and vascular endothelial growth factor. The detection range and thresholds are given in Table S1. For the measurement of IP-10, ELISA (R&D Systems, MN, USA) was performed as well.
Statistical analyses
Continuous variables were compared between groups using the Wilcoxon signed-rank test and the Mann–Whitney U test, and categorical data were compared using the χ 2 test or Fisher’s exact test. The correlations between cytokines, chemokines, and clinical markers were evaluated by Spearman’s correlation coefficient. A p value below 0.05 was considered to be significant. Logistic regression was used for multivariate analyses. All statistical analyses were performed with PRISM and SPSS.
Results
Serum IFN-λ3 levels are increased in patients with chronic HCV infection
The clinical backgrounds of C-CH patients are shown in Table 1. First, we compared serum IFN-λ3 levels among patients with C-CH or chronic hepatitis B (B-CH) and uninfected healthy volunteers (HVs). Such levels in the C-CH group were significantly higher than those in the B-CH group or the HV group (Fig. 1a). The levels in the B-CH group were increased, but the significance of this was much less than in the C-CH group (Fig. 1a). When we compared serum IFN-λ3 levels in B-CH patients between HBeAg-positive and HBeAg-negative patients, we found no difference between them (2.5 ± 0.9 pg/mL vs 1.8 ± 1.7 pg/mL, respectively). Next, we compared serum IFN-λ3 levels between patients with the IFNL3 TT genotype and those with the TG/GG (non-TT) genotype in the C-CH group. Although some patients in the TT group showed relatively higher levels of IFN-λ3 than those in the non-TT group, this difference between the TT and non-TT groups did not reach significance (Fig. 1b). Third, we compared serum IFN-λ3 levels before and after the combination therapy in the relevant cases. In patients who successfully eradicated HCV (SVR), serum IFN-λ3 levels were significantly decreased at 24 weeks after the therapy. In contrast, such levels did not change in those patients who failed to eradicate HCV (transient virological response and no virological response groups, respectively) (Fig. 1c). Fourth, we compared serum IFN-λ3 levels among patients with various causes of acute viral hepatitis. Unfortunately, serum samples from acute hepatitis C patients were not available in this study. The IFN-λ3 levels in the acute hepatitis E group were higher than those in the HVs (Fig. 1d). The IFN-λ3 levels in the acute hepatitis B group tended to be higher than those in the HVs; however, statistical analysis was not performed because of the limited number of samples (N = 2). No significant difference was observed between the acute hepatitis A and HV groups. These results indicate that serum IFN-λ3 levels are increased in patients with C-CH or acute hepatitis E.
Serum IFN-λ3 levels may be related to liver inflammation or fibrosis in patients with C-CH
To explore the clinical significance of IFN-λ3 in chronic HCV infection, we simultaneously examined 27 chemokines and cytokines in serum by means of the BioPlex system, which allows one to measure multiple factors at high sensitivity in a small volume of samples (10 μL per sample). In comparison with the results for HVs, we found that the levels of some chemokines in the C-CH group were higher than those in the HV group, such as IP-10, MIP-1α, MIP-1β, RANTES, and PDGF-BB (Figs. 2, S1).
Next, we examined whether serum IFN-λ3 levels are correlated or not correlated with clinical parameters or immunological markers in the C-CH group. The IFN-λ3 levels were weakly and positively correlated with AST, ALT, and α-fetoprotein levels and histological activity (Table 2). These results indicate that the increase of serum IFN-λ3 levels in patients with C-CH is related to liver inflammation. The FIB-4 score and the APRI are representatives of noninvasive markers of liver fibrosis. The levels of serum IFN-λ3 were positively correlated with the APRI, but not with the FIB-4 score (Table 2). With regard to the chemokines displaying higher values in the C–CH group, the levels of IP-10 and PDGF-BB were positively correlated with the IFN-λ3 levels (Table 2). Such chemokines are reported to be involved in the early stage of liver fibrosis [20–22]. Thus, serum levels of IFN-λ3 may be related to the fibrotic markers as well. To clarify the mechanisms causing the increase of serum IFN-λ3 levels in B-CH patients, we examined the correlations between serum IFN-λ3 levels and clinical markers and fibrosis indices. Serum IFN-λ3 levels were correlated with the levels of AST (r = 0.64, p = 0.03) and total cholesterol (r = −0.76, p = 0.03), FIB-4 score (r = 0.65, p = 0.03), and APRI (r = 0.76, p = 0.007) (Table S2). In addition, serum IFN-λ3 levels tended to be higher in HBV-positive patients with liver cirrhosis or HCC (3.0 ± 3.1 pg/mL in liver cirrhosis patients and 4.1 ± 4.7 pg/mL in HCC patients, respectively) (Fig. S2). These results show that serum IFN-λ3 levels are related to liver inflammation and fibrosis not only in C-CH patients but also in B-CH patients.
Pretreatment serum IFN-λ3 is not related to SVR to PEG-IFN-α plus RBV therapy in patients with C-CH
Because the IFNL3 genotype is a strong predictor of the efficacy of PEG-IFN-α plus RBV therapy for C-CH, we sought to examine the clinical value of serum IFN-λ3 in patients who underwent the combination therapy. In a comparison of the clinical and immunological factors between the SVR and non-SVR groups, univariate analysis revealed that AST, IFNL3 genotype, fibrosis score, and MIP-1α were associated with the SVR (Table 3). However, serum IFN-λ3 or IP-10 levels were not different between the SVR and non-SVR groups (Table 3). Subsequently, multivariate analysis including such factors of significance (p < 0.05 by univariate analysis) showed that IFNL3 SNPs, fibrosis score, and MIP-1α were involved in the SVR (Table 3). These results suggest that serum IFN-λ3 fails to be a predictive marker for SVR in PEG-IFN-α plus RBV therapy.
Discussion
In this study, we demonstrated that serum IFN-λ3 levels were higher in patients with C-CH than in uninfected or HBV-positive patients, the levels in whom did not differ regardless of the IFNL3 genotype. Serum IFN-λ3 levels were correlated with clinical and immunological markers of liver inflammation and fibrosis, suggesting that the production of IFN-λ3 may be regulated by not only the presence or absence of HCV but also by the status of liver disease. It is well acknowledged that IFNL3 genotype is a strong predictor of SVR in PEG-IFN-α plus RBV therapy for C-CH [7–9]. However, serum IFN-λ3 fails to be a surrogate marker for IFNL3 genotype in the combination therapy.
On primary HCV infection, IFN-λ is produced by hepatocytes that subsequently induce antiviral IFN-stimulated genes [23]. Parallel reduction of serum IFN-λ3 levels in C-CH patients who attained SVR by PEG-IFN-α plus RBV treatment indicates that the presence of HCV is involved in the production of IFN-λ3. In addition to hepatocytes, dendritic cells or macrophages are capable of producing IFN-λ in response to HCV [24]. For sensing HCV, hepatocytes and BDCA3+ dendritic cells mainly utilize Toll-like receptor 3 and retinoic acid inducible gene I, and plasmacytoid dendritic cells utilize Toll-like receptor 7 [24, 25]. It is yet to be clarified which cells—hepatocytes or dendritic cells—have stronger potential to secrete IFN-λ at the single-cell level. However, it is rational to consider that serum IFN-λ3 levels in patients are determined by the sum of IFN-λ3 sporadically released from both types of cells. Therefore, it is plausible that the amount of IFN-λ released from hepatocytes or dendritic cells is influenced by the environment of the producers, such as inflammation and fibrosis. A positive correlation observed between serum IFN-λ3 levels and AST levels, FIB-4 score, and APRI in B-CH patients may support such a possibility. In this study, serum IFN-λ3 levels in the B-CH group were higher than those in HVs. However, this difference was slim compared with the difference between the C-CH group and HVs, suggesting that the difference in their genome structure, either RNA or DNA virus, may influence IFN-λ3 production by infected cells. Of interest is the finding that serum IFN-λ3 levels were higher in patients with acute hepatitis E than in patients with acute hepatitis A. It is reported that dendritic cells localized in the intestine are capable of producing IFN-λ in response to rotavirus to protect the host from infection [26]. Although both hepatitis E virus and hepatitis A virus are RNA viruses that are transmissible by the enterofecal route, the difference in serum IFN-λ3 levels suggests that there are distinct mechanisms of recognition of hepatitis E virus and hepatitis A virus by the hosts. Further investigation is needed to disclose which pattern recognition receptors are utilized in hepatocytes or immune cells for the recognition of such viruses to produce IFN-λ.
The regulatory mechanisms of transcription and translation of IFN-λ3 have not been well documented. The IFNL3 SNPs (rs8099917) are located 8.9 kb upstream of the promoter region of the IFNL3 gene [8, 9, 11]. Because of such localization, it is less likely that the genetic variation has some impact on the transcriptional level of IFNL3. With regard to the relationship between the IFNL3 genotype and its transcripts, controversial results have been reported thus far. Some groups reported that IFN-λ3 messenger RNA levels in peripheral blood mononuclear cells were higher in patients with the IFNL3 major genotype than in those with the minor genotype [9]. In contrast, others showed that in hepatocytes such levels were comparable regardless of IFNL3 SNPs. In the search for some genetic factors influencing IFNL3 transcription, Sugiyama et al. [27] reported the existence of variable-length TA repeats in the promoter of the IFNL3 gene. Other investigators showed that a certain structure of the 3′ untranslated region in the IFNL3 gene is involved in the durability/stability of the gene [28]. Nevertheless, the contribution of such factors is not enough to fill in the gap, suggesting that certain other regulatory factors for IFNL3 are still to be revealed.
Reports concerning serum IFN-λ in C-CH patients are limited. Langhans et al. [29] showed that serum levels of IFN-λ, which includes IFN-λ2 and IFN-λ3, were higher in patients with the IFNL3 major genotype than in those with the minor genotype. One of the limitations of their study seems to be the lack of specificity for the measurement of IFN-λ3. Since the homology of IFNL2 (which encodes IFN-λ2) and IFNL3 is quite high, it is difficult to quantify specifically IFN-λ3 by excluding contamination by IFN-λ2. To exclude such a possibility, we used the newly developed chemiluminescence enzyme immunoassay for IFN-λ3, which enables one to quantify IFN-λ3 without any influence from IFN-λ2 in the range from 0 to 1,000 pg/mL. By means of this system, we found that serum levels of IFN-λ3 are not statistically different between patients with the IFNL3 major genotype and those with the minor genotype.
On primary HCV exposure, the significance of IFN-λ family members as an antiviral protein is evident. However, such impact of IFN-λ3 in chronically HCV-infected patients is still elusive. Langhans et al. [29] reported that serum IFN-λ levels in patients who had spontaneously cleared HCV were higher than in patients with chronic HCV infection, implying that a higher level of IFN-λ somewhat contributed to HCV eradication. In this study, we aimed to clarify the significance of IFN-λ3 in patients with chronic HCV infection with different approaches. Firstly, we searched for the factors influencing serum IFN-λ3 quantity by correlation analysis with clinical markers and multiple cytokines/chemokines. We found that AST, ALT, and α-fetoprotein levels and histological activity were positively correlated with serum IFN-λ3 levels. In addition, one of the noninvasive fibrosis markers, APRI, was weakly correlated with serum IFN-λ3 levels. Among the chemokines examined in this study, serum IFN-λ3 was positively correlated with IP-10 and PDGF-BB. IP-10 (CXCL10) is induced in HCV-infected hepatocytes as one of the IFN-stimulated genes, and attracts CXCR3-positive T cells and natural killer cells and subsequently activates inflammation. IP-10 is also reported to be involved in the early stage of liver fibrosis [30, 31]. A similar fibrotic function was reported for PDGF-BB, the level of which is reported to be increased in patients with advanced/fibrosis stages of HBV infection [32, 33]. These reports support the notion that IFN-λ3 is related to liver inflammation and fibrosis. As well as in B-CH patients, a positive correlation was observed between serum IFN-λ3 levels and inflammation (AST levels) and fibrosis markers (FIB-4 score and APRI). Secondly, we examined whether serum IFN-λ3 and chemokines are involved or not involved in the SVR to PEG-IFN-α plus RBV therapy for C-CH patients. We confirmed that IFNL3 genotypes, fibrosis score, and MIP-1α are associated with SVR in this cohort, but failed to do so with IP-10 and serum IFN-λ3. Several studies showed that pretreatment IP-10 levels could be a predictor of SVR in PEG-IFN-α plus RBV therapy for C-CH [34], the significance of which became stronger in combination with IFNL3 genotypes [35, 36]. One of the reasons why the IP-10 levels failed to be significant in this study may be a bias for the enrollment of patients from multiple hospitals and medical centers.
In summary, serum IFN-λ3 levels are increased in patients with chronic HCV infection regardless of the IFNL3 genotype, the level of which is associated with liver inflammation and fibrosis. The biological role and clinical impact of IFN-λ3 in patients with chronic HCV infection need to be investigated further.
Abbreviations
- APRI:
-
Aspartate aminotransferase platelet ratio index
- ALT:
-
Alanine aminotransferase
- AST:
-
Aspartate aminotransferase
- B-CH:
-
Chronic hepatitis B
- C-CH:
-
Chronic hepatitis C
- FIB-4:
-
Fibrosis-4
- HBV:
-
Hepatitis B virus
- HCC:
-
Hepatocellular carcinoma
- HCV:
-
Hepatitis C virus
- HIV:
-
Human immunodeficiency virus
- HV:
-
Healthy volunteer
- IFN:
-
Interferon
- IP-10:
-
Interferon-γ-inducible protein 10
- MIP:
-
Macrophage inflammatory protein
- PDGF-BB:
-
Platelet-derived growth factor BB
- PEG-IFN-α:
-
Pegylated interferon-α
- RANTES:
-
Regulated on activation, normally T cell expressed, and secreted
- RBV:
-
Ribavirin
- SNP:
-
Single nucleotide polymorphism
- SVR:
-
Sustained virological response
References
Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–8.
Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41(1):17–27.
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907–17.
Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future. N Engl J Med. 2014;370(21):2043–7.
Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56(Suppl 1):S88–100.
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9.e18.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.
Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887–98.
Kotenko SV. IFN-λs. Curr Opin Immunol. 2011;23(5):583–90.
Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978–88.
Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40(1):8–13.
Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44.
Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1):15–20.
Ogawa E, Furusyo N, Shimizu M, et al. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antivir Ther. 2014. doi:10.3851/IMP2805.
Teshale E, Lu M, Rupp LB, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat. 2014;21(12):917–20.
Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49(5):1853–60.
Sugiyama M, Kimura T, Naito S, et al. Development of specific and quantitative real-time detection PCR and immunoassays for λ3-interferon. Hepatol Res. 2012;42(11):1089–99.
Melton AC, Yee HF. Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. Hepatology. 2007;45(6):1446–53.
Wasmuth HE, Tag CG, Van de Leur E, et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology. 2009;49(3):775–80.
Ogawa S, Ochi T, Shimada H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res. 2010;40(11):1128–41.
Park H, Serti E, Eke O, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology. 2012;56(6):2060–70.
Yoshio S, Kanto T, Kuroda S, et al. Human blood dendritic cell antigen 3 (BDCA3)+ dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology. 2013;57(5):1705–15.
Stone AE, Giugliano S, Schnell G, et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 2013;9(4):e1003316.
Pott J, Mahlakoiv T, Mordstein M, et al. IFN-λ determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A. 2011;108(19):7944–9.
Sugiyama M, Tanaka Y, Wakita T, et al. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One. 2011;6(10):e26620.
McFarland AP, Horner SM, Jarret A, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014;15(1):72–9.
Langhans B, Kupfer B, Braunschweiger I, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011;54(5):859–65.
Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74(3):360–9.
You CR, Park SH, Jeong SW, et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver. 2011;5(4):506–12.
Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54(6):2076–88.
Patsenker E, Popov Y, Wiesner M, et al. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007;46(5):878–87.
Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617–25.
Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011;53(1):14–22.
Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011;6(2):e17232.
Acknowledgment
This study was supported by grants (23-105) from the National Center for Global Health and Medicine in Japan.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Y. Aoki and M. Sugiyama contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
535_2014_1023_MOESM1_ESM.tif
Supplementary material 1. Multiple cytokine/chemokine analysis in patients with chronic HCV infection and uninfected healthy volunteers.Serum cytokine and chemokine were quantified by means of multiplexed Bio-Plex system as described in Materials and Methods. IP-10 was assayed by ELISA and are shown in Fig2. IL-2 was not measurable in this study.C-CH: chronic hepatitis C patients, HV: healthy volunteers(TIFF 66 kb)
535_2014_1023_MOESM2_ESM.tif
Supplementary material 2. Serum IFN-3 levels in HBV infection are not different among patients with different stages of chronic liver disease.Serum IFN-3 levels in patients with asymptomatic HBV carriers (B-ASC, N=21), chronic hepatitis B (B-CH, N=11), liver cirrhosis (B-LC, N=8) and hepatocellular carcinoma (B-HCC, N=4) were quantified by CLEIA method as described in Materials and Methods. (TIFF 36 kb)
Rights and permissions
About this article
Cite this article
Aoki, Y., Sugiyama, M., Murata, K. et al. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol 50, 894–902 (2015). https://doi.org/10.1007/s00535-014-1023-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-014-1023-2